Abstract: Globally, cancer is the biggest cause of death. Many chemotherapy medications have been widely utilized to treat cancer. Current anticancer medications, however, lead to resistance and serious adverse effects. Thus, it's critical to find new, potent anticancer drugs with few or no adverse effects. Interestingly, natural substances have been emphasized as anticancer medications. By preventing cancer side effects such as nausea, bone marrow suppression, anaemia, and decreased resistance, mushrooms are known to support chemotherapy and radiation therapy. Several bioactive compounds, including anti-tumour drugs, have recently been discovered in a variety of mushrooms. Among them, mushrooms with biological properties, such as anticancer activity, have drawn the attention of several researchers. Discussing the anticancer potential of various mushrooms and the underlying molecular pathways is the goal of this review. Phellinus, Pleurotus, Agaricus, Ganoderma, Clitocybe, Antrodia, Trametes, Cordyceps, Xerocomus, Calvatia, Schizophyllum, Flammulina, Suillus, Inonotus, Inocybe, Funalia, Lactarius, Albatrellus, Russula, and Fomes are among the genera of mushrooms that have been linked to cancer prevention. Inducing reactive oxygen species, inhibiting mitotic kinase, preventing angiogenesis, inhibiting topoisomerase, causing apoptosis, and ultimately halting the spread of cancer are all important functions of anti-cancer drugs. We include information on the numerous mushrooms and substances generated from them, including their current clinical status and potential molecular mechanisms of action. Researchers and medical professionals may find this study useful in creating evidence-based preclinical and clinical studies to evaluate the anti-cancer potential of mushrooms. This review incorporates all the reviews on mushrooms as anti-cancer agents.
Pal et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: